PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

M.T. Dillon; Z. Boylan; D. Smith; J. Guevara; K. Mohammed; C. Peckitt; M. Saunders; U. Banerji; G. Clack; S.A. Smith; J.F. Spicer; M.D. Forster; K.J. Harrington

doi:10.1016/j.ctro.2018.06.001

Enriched recordOpen access

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

M.T. Dillon, Z. Boylan, D. Smith, J. Guevara, K. Mohammed, C. Peckitt, M. Saunders, U. Banerji, G. Clack, S.A. Smith, J.F. Spicer, M.D. Forster, K.J. Harrington

Clinical and Translational Radiation Oncology2018doi:10.1016/j.ctro.2018.06.001

Citation graph

Abstract

PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.

Open public full text

Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN

Authors

M.T. Dillon#1 Z. Boylan#2 D. Smith#3 J. Guevara#4 K. Mohammed#5 C. Peckitt#6 M. Saunders#7 U. Banerji#8 G. Clack#9 S.A. Smith#10

Referenced works

View all references →

No local reference links have been materialized yet.

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

Radiotherapy demand and activity in England 2006–2020

10.1016/j.clon.2013.05.005 · 2013

Human papillomavirus-negative pharyngeal cancer

10.1200/jco.2015.60.7804 · 2015

Selective targeting of the G2/M cell cycle checkpoint to improve the therapeutic index of radiotherapy

10.1016/j.clon.2014.01.009 · 2014

Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei

10.1158/1535-7163.mct-16-0239 · 2017

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

10.4161/cbt.21093 · 2012

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

10.1038/bjc.2012.265 · 2012

Targeted radiosensitization by the Chk1 inhibitor SAR-020106

10.1016/j.ijrobp.2012.08.006 · 2013

Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776

10.1158/1078-0432.ccr-12-3748 · 2013

Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair

10.1158/0008-5472.can-09-3573 · 2010

Abstract 2348: discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients

PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

Referenced works

Cited by

External reference records

Additional external references